Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma

References

• Callahan MK, Flaherty CR, Postow MA. Checkpoint blockade for the treatment of advanced melanoma. Cancer Treat Res 2016; 167:231-50; PMID:26601865; http://dx.doi.org/10.1007/978-3-319-22539-5_9
   PubMedGoogle Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 2016; 114(10):1084-9; PMID:27124339; http://dx.doi.org/10.1038/bjc.2016.107
   PubMed Web of Science ®Google Scholar
• Borodic GE, Hinkle D. Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2014; 30:83; PMID:24398505; http://dx.doi.org/10.1097/IOP.0000000000000033
   PubMed Web of Science ®Google Scholar
• Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 2011; 197:W992-W1000; PMID:22109345; http://dx.doi.org/10.2214/AJR.10.6198
   PubMed Web of Science ®Google Scholar
• Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99:4078-85; PMID:25078147; http://dx.doi.org/10.1210/jc.2014-2306
   PubMed Web of Science ®Google Scholar
• Henderson AD, Thomas DA. A case report of orbital inflammatory syndrome secondary to ipilimumab. Ophthal Plast Reconstr Surg 2015; 31:e68-70; PMID:24814274; http://dx.doi.org/10.1097/IOP.0000000000000081
   PubMedGoogle Scholar
• Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 2009; 36:518-20; PMID:19650371; http://dx.doi.org/10.1017/S0317167100007939
   PubMed Web of Science ®Google Scholar
• Lecouflet M, Verschoore M, Giard C, Gohier P, Le Corre Y, Milea D, Martin L. Orbital myositis associated with ipilimumab. Ann Dermatol Venereol 2013; 140:448-51; PMID:23773743; http://dx.doi.org/10.1016/j.annder.2013.02.029
   PubMed Web of Science ®Google Scholar
• McElnea E, Ni Mhealoid A, Moran S, Kelly R, Fulcher T. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 2014; 33:424-7; PMID:25207976; http://dx.doi.org/10.3109/01676830.2014.949792
   PubMedGoogle Scholar
• Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164:303-7; PMID:21088057; http://dx.doi.org/10.1530/EJE-10-0833
   PubMed Web of Science ®Google Scholar
• Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM. Ipilimumab-induced Ocular and Orbital Inflammation-A Case Series and Review of the Literature. Ocul Immunol Inflamm 2016; 24:140-6; PMID:25760920
   PubMed Web of Science ®Google Scholar
• Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, Vleugels RA. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015; 151:195-9; PMID:25321335; http://dx.doi.org/10.1001/jamadermatol.2014.2233
   PubMed Web of Science ®Google Scholar
• Sheldon CA, Kharlip J, Tamhankar MA. Inflammatory orbitopathy associated with ipilimumab. Ophthal Plast Reconstr Surg 2015; PMID:26068559; http://dx.doi.org/10.1097/IOP.0000000000000509
   PubMedGoogle Scholar
• Gathings R, Lewallen R, Yosipovitch G. Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature. Acta Derm Venereol 2015; 95:197-200; PMID:24820241; http://dx.doi.org/10.2340/00015555-1897
   PubMed Web of Science ®Google Scholar
• Bouwhuis MG, Ten Hagen TL, Eggermont AM. Immunologic functions as prognostic indicators in melanoma. Mol Oncol 2011; 5:183-9; PMID:21367679; http://dx.doi.org/10.1016/j.molonc.2011.01.004
   PubMed Web of Science ®Google Scholar
• Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM. Auto immunity and treatment outcome in melanoma. Curr Opin Oncol 2011; 23:170-6; PMID:21150603; http://dx.doi.org/10.1097/CCO.0b013e328341edff
   PubMed Web of Science ®Google Scholar
• Bottoni U, Paolino G, Ambrifi M, Didona D, Albanesi M, Clerico R, Lido P, Brachini A, Corsetti P, Richetta AG, et al. Association between autoimmune disease and cutaneous melanoma with regard to melanoma prognosis. Clin Exp Dermatol 2015; 40:254-9; PMID:25475359; http://dx.doi.org/10.1111/ced.12531
   PubMed Web of Science ®Google Scholar